December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AngioDynamics, Inc. - Common Stock (NQ:ANGO)

15.30 +0.03 (+0.20%)
Streaming Delayed Price Updated: 2:45 PM EDT, Sep 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 117,535
Open 15.32
Bid (Size) 15.29 (200)
Ask (Size) 15.31 (200)
Prev. Close 15.27
Today's Range 15.11 - 15.51
52wk Range 9.390 - 16.29
Shares Outstanding 38,444,076
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
AngioDynamics Sees MedTech Becoming Majority of Revenue in Fiscal 2027 ↗
AngioDynamics (NASDAQ:ANGO) expects its MedTech business to become the majority of company revenue in fiscal 2027, as the company continues a multiyear shift away from slower-growth legacy markets and... 
Via MarketBeat
News headline image
AngioDynamics to Participate in Upcoming Investor Conferences
From AngioDynamics, Inc.
Via Business Wire

Performance

YTD
+20.7%
+20.7%
1 Month
-3.5%
-3.5%
3 Month
+27.7%
+27.7%
6 Month
+43.4%
+43.4%
1 Year
+45.7%
+45.7%

More News

Read More
News headline image
AngioDynamics (ANGO) Q4 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings World Trade
News headline image
AngioDynamics Q4 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
AngioDynamics (NASDAQ:ANGO) Surges on Strong Quarterly Beat as Med Tech Segment Drives Growth ↗
Via Chartmill
AngioDynamics Inc (NASDAQ:ANGO) Beats Q3 Earnings Estimates and Raises Full-Year Guidance ↗
Via Chartmill
News headline image
Full Transcript: AngioDynamics Q4 2026 Earnings Call ↗
Via Benzinga
Topics Earnings
News headline image
AngioDynamics Reports Record Fiscal Year 2026 Fourth Quarter and Full Year Financial Results; Continued Execution Drives Med Tech Growth and Full-Year Profitability
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics to Report Fiscal 2026 Fourth Quarter and Full-Year Financial Results on July 14, 2026
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics Receives FDA IDE Approval for RELIEF Feasibility Study Evaluating NanoKnife IRE Platform as Minimally Invasive Treatment for Benign Prostatic Hyperplasia (BPH)
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics Expands Patient Access to NanoKnife IRE for Prostate and Liver Cancer as Medicare Coverage Framework Takes Effect
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics Announces Two-Year PRESERVE Trial Data Demonstrating Durable NanoKnife IRE System Outcomes in Intermediate-Risk Prostate Cancer
From AngioDynamics, Inc.
Via Business Wire
News headline image
Med-Tech Resilience: AngioDynamics Pivot Pays Off with Double-Digit Growth and Profitability
Via MarketMinute
Topics Economy Retirement
News headline image
AngioDynamics Reports Fiscal Year 2026 Third Quarter Financial Results; Sustained Double-Digit Med Tech Growth Drives Continued Profitability
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics to Present at the 25th Annual Needham Virtual Healthcare Conference
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics to Report Fiscal 2026 Third Quarter Results on April 2, 2026
From AngioDynamics, Inc.
Via Business Wire
News headline image
Bastion Bets on Government Spending with $8 Million New Stake in Parsons ↗
Via The Motley Fool
News headline image
AngioDynamics to Present at the Leerink Partners Global Healthcare Conference
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics Expands Indications for the NanoKnife System Across Europe, Strengthening Multi-Organ Tumor Ablation Platform
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics and The PERT Consortium® Launch Investigator-Led Research Fund to Advance Pulmonary Embolism Care
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics to Convene Cardiovascular Leaders at Scientific Forum as Pipeline Continues to Advance
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics (ANGO) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
Topics World Trade
News headline image
AngioDynamics (ANGO) Q3 2025 Earnings Transcript ↗
Via The Motley Fool
News headline image
AngioDynamics (ANGO) Q1 2025 Earnings Transcript ↗
Via The Motley Fool
Topics Economy

Frequently Asked Questions

Is AngioDynamics, Inc. - Common Stock publicly traded?
Yes, AngioDynamics, Inc. - Common Stock is publicly traded.
What exchange does AngioDynamics, Inc. - Common Stock trade on?
AngioDynamics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for AngioDynamics, Inc. - Common Stock?
The ticker symbol for AngioDynamics, Inc. - Common Stock is ANGO on the Nasdaq Stock Market
What is the current price of AngioDynamics, Inc. - Common Stock?
The current price of AngioDynamics, Inc. - Common Stock is 15.30
When was AngioDynamics, Inc. - Common Stock last traded?
The last trade of AngioDynamics, Inc. - Common Stock was at 09/14/26 02:45 PM ET
What is the market capitalization of AngioDynamics, Inc. - Common Stock?
The market capitalization of AngioDynamics, Inc. - Common Stock is 588.19M
How many shares of AngioDynamics, Inc. - Common Stock are outstanding?
AngioDynamics, Inc. - Common Stock has 588M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.